Flupenthixol Decanoate in Methamphetamine Smoking - 1

This study has been completed.

First Received on September 20, 1999. Last Updated on June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Friends Research Institute, Inc.
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000241

Purpose

The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate for treatment of methamphetamine dependence. Also, study will compare flupenthixol with desipramine in blocking methamphetamine self-administration.

Condition	Intervention	Phase
Substance-Related Disorders	Drug: Flupenthixol	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Flupenthixol Decanoate in Methamphetamine Smoking

Resource links provided by NLM:

MedlinePlus related topics: Drug Abuse Methamphetamine Smoking

Drug Information available for: Methamphetamine hydrochloride Flupenthixol decanoate Amphetamine Methamphetamine Flupenthixol

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Methamphetamine use

Estimated Enrollment:	58
Study Start Date:	February 1994
Estimated Study Completion Date:	May 1996

Eligibility

Ages Eligible for Study:	22 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000241

Locations

United States, California
Friends Research Institute
Los Angeles, California, United States, 90025

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Friends Research Institute, Inc.

Investigators

Principal Investigator:

Frank Gawin, M.D.

Friends Research Institute, Inc.

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000241 History of Changes
Other Study ID Numbers:	NIDA-07200-1, R01-07200-1
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Substance-Related Disorders
Mental Disorders
Flupenthixol
Flupenthixol decanoate
Methamphetamine
Amphetamine
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Antipsychotic Agents

Tranquilizing Agents
Central Nervous System Depressants
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Central Nervous System Stimulants
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors

ClinicalTrials.gov processed this record on February 09, 2012